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Cyclooxygenase-2 (COX-2) is associated with poor-prognosis breast cancer. We used a nude mouse xenograft model to determine
the effects of COX-2 inhibition in breast cancer. Oestrogen receptor (ER)-positive MCF7/HER2-18 and ER-negative MDAMB231
breast cancer cell lines were injected into nude mice and allowed to form tumours. Mice then received either chow containing
Celecoxib (a COX-2 inhibitor) or control and tumour growth measured. Tumour proliferation, apoptosis, COX-2,
lymphangiogenesis and angiogenesis were assessed by immunohistochemistry (IHC), Western blotting or Q-PCR. Celecoxib
inhibited median tumour growth in MCF7/HER2-18 (58.7%, P¼0.029) and MDAMB231 (46.3%, P¼0.0002) cell lines compared to
control. Cyclooxygenase-2 expression decreased following Celecoxib treatment (MCF7/HER2-18 median control 65.3% vs treated
22.5%, P¼0.0001). Celecoxib increased apoptosis in MCF7/HER2-18 tumours (TUNEL 0.52% control vs 0.73% treated, P¼0.0004)
via inactivation of AKT (median pAKT
ser473 57.3% control vs 35.5% treated, P¼0.0001 – confirmed at Western blotting). Q-PCR
demonstrated decreased podoplanin RNA (lymphangiogenesis marker) in the MCF7/HER2-18 – median 2.9 copies treated vs 66.6
control (P¼0.05) and MDAMB231-treated groups – median 160.7 copies vs 0.05 control copies (P¼0.015), confirmed at IHC.
Cyclooxygenase-2 is associated with high levels of activated AKT
ser473 and lymphangiogenesis in breast cancer. Cyclooxygenase-2
inhibition decreases tumour growth, and may potentially decrease recurrence, by inactivating AKT and decreasing lymphangiogenesis.
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Cyclooxygenase-2 (COX-2) is overexpressed in approximately 70%
of cases of in situ and 60% of invasive breast cancer (Boland et al,
2004). The COX genes encode for enzymes that catalyse the rate-
limiting step of conversion from arachidonic acid to prosta-
glandins. Two main isoforms, COX-1 and COX-2, were first
demonstrated in the early 1990s (Fu et al, 1990; Xie et al, 1991).
Cyclooxygenase-1 is constitutively expressed in most tissues, and
is responsible for physiological housekeeping functions such as
gastric cytoprotection, regulation of renal blood flow and platelet
aggregation (Smith et al, 2000). Cyclooxygenase-2 is an inducible
isoform, and is expressed by cells involved in the inflammatory
process (Subbaramaiah et al, 1996; Smith et al, 2000) (i.e.
macrophages, monocytes, synoviocytes) and also in a wide variety
of solid epithelial tumours (Gasparini et al, 2003). The increased
expression of COX-2 in tumourigenesis is secondary to multiple
activations and as a response to growth factors and oncogenes,
including those in the EGFR/HER2/RAS/MAP kinase pathway.
This latter pathway is of particular interest in breast cancer as
HER2 is often upregulated in both invasive and in situ disease and
is associated with poor prognosis tumours (Slamon et al, 1987;
Sposto and Silverstein, 2002). Conversely, COX-2 is rarely
expressed in normal tissue (unless in proximity to an area of
neoplasia or inflammation). When COX-2 is expressed in normal
tissue, it has been found in a subpopulation of normal breast cells
with silenced p16
ink4a (which have been postulated as precursors of
breast cancer) (Crawford et al, 2004).
Studies of transgenic mice engineered to overexpress COX-2
have shown that these mice form mammary tumours earlier and
more often than wild-type mice, their mammary glands contain
fewer apoptotic cells and show reduced expression of the
proapoptotic proteins BAX and BCl-x(L) (Liu et al, 2001). Elevated
COX-2 expression leads to increased tumour recurrence and
decreased survival in invasive breast cancer (Crawford et al, 2004).
The recent publication of the Women’s Health Initiative results
(Harris et al, 2003) suggest that the regular use of nonsteroidal
anti-inflammatory drugs (NSAIDs) has a significant chemo-
preventative effect against developing breast cancer, with a 28%
reduction (relative risk 0.72, 95% CI 0.56–0.91) with regular
NSAID use for 10 years or more.
Previous studies have shown significant decreases in various
solid tumour growths following the administration of COX-2
inhibitors (Connolly et al, 2002; Howe et al, 2002), although there
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sis still a need to clarify the mechanism of action in breast cancer
and identify surrogate markers of effect.
The aims of this study were to use a xenograft model of breast
cancer to confirm the effect of COX-2 inhibition on tumour growth
in vivo, and to subsequently determine the mechanism of action,
by studying expression of markers of cell proliferation (Ki67 and
p21
cip1), apoptosis (TUNEL) and AKT activation.
We also aimed to determine whether Celecoxib perturbed the
production of the new lymphatic vessels (lymphangiogenesis). It
has recently been demonstrated that expression of the lymph-
angiogenic factor VEGF-C is significantly elevated in cells over-
expressing COX-2 (Su et al, 2004). The production of new
lymphatic vessels by the tumour is a key step in the promotion
of cancer metastasis and COX-2 inhibitors have been shown to
have antimetastatic activity in a metastatic mouse model (Roche-
Nagle et al, 2004). In addition, markers of tumour endothelial cell
formation have been shown to correlate with prognosis in breast
cancer (Davies et al, 2004). In this paper, we used podoplanin, a
marker of lymphatic endothelial cells to demonstrate changes in
lymphangiogenesis following treatment with Celecoxib in our
xenograft model.
MATERIALS AND METHODS
Tumour cell lines
One oestrogen receptor (ER)-positive and one ER-negative breast
cancer cell line were chosen for study. MCF7/HER2-18, is an
ER-positive MCF7 cell line which had been stably transfected
with HER2 (EGFR negative /HER2 positive/ER positive), a gift from
Professor CC Benz, University of California San Francisco, and
MDAMB231 is an ER-negative breast cancer cell line which is
EGFR positive /HER2 negative. All cells were routinely maintained
in Dulbecco’s Modified Eagle Medium with 10% foetal calf serum,
2m M glutamine, 100U penicillin and 100mg streptomycin per
500ml. The cells were incubated at 371C in a humidified
environment and passaged at near confluence.
Nude mouse xenograft model
The experimental design followed a well-established female nude
mouse model from our department (Gandhi et al, 2000; Chan et al,
2002). Following ethical approval, 2–4 million cells were injected
into each flank of female BLAB/c nu/nu mice, aged 6–8 weeks,
and allowed to form tumours. The tumours were measured with
callipers twice weekly (length width) and the mice weighed. The
mice had free access to feed, water and bedding at all time, and
were housed with a 12h light/dark cycle in filter top cages,
maximum six mice per cage.
Tumour volumes (mm
3) were calculated by the formula
length length (width/2). When 475% of the tumours were
palpable the mice were randomised to receive either chow
containing 0.15% Celecoxib (Celecoxib donated from Pfizer/chow
constituted at Purina Mills, USA) or control chow. The tumours
continued to be measured and the mice weighed twice weekly.
When tumours in either group reached 1cm
3, the experiment was
ended in accordance with UK Home Office guidelines and the
tumours were harvested. The tumours were then split, with half
fixed in 4% formalin and embedded in paraffin blocks for
immunohistochemistry (IHC), and the remainder snap frozen in
liquid nitrogen.
Immunohistochemistry
Three micron sections of the paraffin blocks were cut onto APES-
coated slides. The slides were dewaxed in xylene and rehydrated
through graded alcohols to PBS. Staining for COX-2 and Ki67
(Boland et al, 2004) was as described previously. All incubations
were carried out at room temperature unless otherwise stated. For
p21, pAkt
ser473 and podoplanin, endogenous peroxidase activity
was blocked by immersing slides in 0.2% H2O2 in methanol for
10min. At TUNEL staining, sections were treated with proteinase
K for 15min before quenching endogenous peroxidase activity.
Antigen retrieval was performed by immersing slides in citrate
buffer (pH 6), in a pressure cooker for p21 (120s), pAkt
ser473
(100s) and podoplanin (120s).
TUNEL
Sections were incubated in equilibration buffer (Apoptag Kit,
Intergen, Norcross, GA, USA) for 1h. Then working strength TdT
enzyme was applied to the sections, which were incubated for 1h
at 371C. Immersing the sections in working strength stop buffer for
10min halted the reaction. Following washing in PBS, the sections
were incubated with anti-digoxigenin conjugate for 30min.
p21
cip1
Sections were incubated with the Mouse-on-Mouse (MOM) kit
blocking solution with avidin for 1h. Following washing in PBS,
the sections were incubated for 5min with the working solution of
MOM dilutent for 5min, and then incubated with the primary
mouse anti-p21 antibody (DAKO M7202 mouse monoclonal) 1:25
made up in MOM dilutent with biotin for 60min. Following
washing in PBS, sections were incubated with working MOM kit
biotinylated anti-mouse IgG for 30min.
Phosphorylated Akt
ser473
Nonspecific binding was blocked with 10% normal goat serum in
PBS with avidin for 15min. The sections were then incubated with
the primary phosphor-AKT/PKB
ser473 antibody (rabbit polyclonal,
Cell Signalling Technology, Danvers, MA, USA, #9277) 1:30 in
10% normal goat serum with biotin for 2h, then with the
biotinylated goat anti-rabbit secondary 1:200 (Vector BA1000) in
10% normal goat serum for 1h.
Podoplanin
Nonspecific binding was blocked by incubating slides in 10%
normal rabbit serum in PBS with avidin for 30min, the slides
were then incubated with the primary monoclonal antibody to
podoplanin (ab11936, AbCam) 1:500 made up in 10% normal
rabbit in PBS with biotin for 2h. After washing in PBS, the
biotinylated rabbit anti-hamster secondary was added (1:500
ab6782 AbCam) for 1h.
For p21, pAkt
ser473, and podoplanin, following the secondary
antibody, sections were incubated with Vectastain Elite ABC
reagent (Vector, Peterborough, UK) for 30min. All stainings were
visualised with DAB, counter-stained with haematoxylin, slides
then dehydrated, cleared and mounted.
IHC scoring
All scorings were carried out blind to the treatment group. For
Ki67, p21
cip1 and pAkt
ser473, the percentage of positive nuclei out of
at least 1000 counted, was determined over representative tumour
areas. At least 3000 cells were counted when determining the
TUNEL score, as there were few apoptotic cells in each specimen.
Reproducibility and accuracy of the scoring was ensured by repeat
scoring and multiple observer scoring of the initial samples. For
pAkt
ser473 the cytoplasmic staining intensities were scored on a
rating 0–3þ. The COX-2 cytoplasmic staining was scored on
both the percentage of positive cells and the staining intensity
for the MCF7/HER2-18. The grading of intensity for each section
was determined following reference to sections taken to be
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srepresentative for each grade of intensity; 0¼no staining, 1¼mild
staining, 2¼moderate staining, 3¼strong, 4¼very strong. At
least 1000 cells were also counted for each section, and the
percentage of positively staining cells determined, and assigned a
numerical score; 1¼no staining, 2¼o10%, 3¼11–50%, 4X50%.
It was considered inappropriate to use the intensity score for the
MDAMB231 cells, as COX-2 expression was localised to cytoplas-
mic vesicles, and there was no discernable difference in intensity.
Scoring was therefore calculated from the proportion of cells
containing cytoplasmic vesicles. All scorings were carried out
using a light microscope, grid graticule and cell counter at  400
magnification. For podoplanin, vessel density was calculated using
a Chalkley point graticule. Scoring was taken as the median
number of vessels crossing the points, from six separate fields of
high vessel density, at  400 magnification.
Western blotting
Snap frozen tumour samples were utilised for Western blotting.
Crushing the tissue samples in liquid nitrogen created tumour
powder. Lysis buffer was then added to create cell lysates, which
were left on ice for 40min before centrifugation (at 13000r.p.m.
for 10min at 41C) and protein estimation (using the Biorad protein
assay solution and a GeneQuant pro machine).
Following the addition of sample buffer to the lysates, 50mgo f
protein was resolved onto SDS gel and transferred to Hybond
membranes using a TRIS/glycine/SDS electrode tank buffer, run
overnight. Membranes were blocked with 5% skimmed milk–TBS-
Tween for 1h and then probed with the primary antibodies; pPKB/
pAKT
ser473 (1:1000 #9271 Cell Signaling Technology) and then
total PKB/AKT (1:1000 #9272 Cell Signaling Technology) as a
loading control.
After washing in TBS-Tween, the membranes were incubated
with a donkey anti-rabbit HRP-linked secondary antibody (1:1000
Amersham Biosciences NA934V, Piscataway, NJ, USA) for 1h.
Following thorough washing in TBS-Tween for 6 10min, the
level of specific protein was visualised by chemiluminescence
(Supersignal West Dura extended duration substrate; Pierce
Biotechnology, Rockford, IL, USA). Both total PKB/AKT and
pPKB/AKT
ser473 bring up single bands of 60kDa. Quantification of
protein levels was estimated at subsequent densitometry using
GeneTools from Syngene version 3.05.
Q-RT-PCR
The assessment of lymphangiogenesis (podoplanin) and angio-
genesis (CD31) was determined by quantitative PCR utilising snap-
frozen tumour samples, which were stored in liquid nitrogen until
use. Samples were homogenised to extract RNA using RNA-Zol
reagent (Abgene homogenisation kit, Epsom, UK) as per
manufacturer’s instructions. cDNA was subsequently generated
from 1mg of RNA using the Enhanced Avian Reverse Transcriptase
kit (Abgene, UK). Levels of podoplanin and CD31 transcripts were
estimated using the Ampliflour Uni Primer detection kit (Intergen,
UK) and 2 Q-PCR master mix according to manufacturers
instructions. Quantification was carried out using the iCycler iQt
(Bio-Rad, Hemel Hempstead, UK). Detection of the fluorescence
was carried out during the annealing step. Copy numbers for
podoplanin and CD31 expression in the samples were determined
from in-house standard curves.
Statistical analysis
Statistical analysis was performed using the Stats Direct statistical
software package and the Mann–Whitney U test for continuous
variables. All tests were two-tailed with a 5% significance level used
throughout.
RESULTS
Tumour growth
There was decreased tumour growth following Celecoxib treatment
in both the MCF7/HER2-18 (P¼0. 029) and MDAMB231 breast
cancer cell lines (P¼0.0003) (Table 1). These results represent the
median values from a total of 43 controls and 41 treated tumours
in the MCF7/HER2-18 cell line and 19 controls and 20 treated
tumours in the MDAMB231 cell line. The median tumour growth
inhibition (TGI) was calculated by comparing the median control
growth to the individual treated tumour growth as shown by the
equation:
TGIð%Þ¼ ð 1  ð individualtreatedgrowth=
mediancontrolgroupgrowthÞÞ 100
The median TGI was 58.7% in the MCF7/HER2-18 tumours and
46.3% in the MDAMB231 tumours (Table 1). No differences in
weight between control and treated mice were seen.
Celecoxib does not perturb cell proliferation
The differences in tumour growth were not a product of alterations
in cell proliferation as there was no change in the median number
of proliferating cells in the cell lines between the control and the
treated samples as assessed by Ki67 (Table 1). Also, the p21
cip1
pathway was not perturbed by the administration of Celecoxib, as
there were no significant changes in the median number of cells in
each cell line expressing p21
cip1 (Table 1).
Table 1 Tumour growth, proliferation and apoptosis in the cell lines studied
Cell line
MCF7 HER2/18 MDAMB231
Control Treated P-value Control Treated P-value
Median growth (mm
3) 100.8 (38.4–183.5) 39.3 (4.0–156.1) 0.029 96.4 (51.3–284.4) 29.7 (0.0–53.3) 0.0003
Median tumour growth inhibition (%) 58.7 ( 7.3–98.2) 46.3 (3.7–97.4)
Mouse weight gain (g) 0.1 (0.7–1.2) 0.8 (0.1–1.6) 0.08 1.9 (1.7–2.0) 2.2 (1.7–2.6) 0.22
Median Ki67 (%) 55.0 (50.9–68.9) 55.5 (47.8–63.0) 0.65 55.1 (47.2–71.6) 57.9 (47.7–60.0) 0.91
Median p21
cip1 (%) 14.5 (12.1–17.0) 16.8 (13.1–20.9) 0.07 0.6 (0.2–2.9) 0.3 (0.1–0.3) 0.88
Median TUNEL (%) 0.52 (0.40–0.63) 0.73 (0.58–0.85) 0.0004 0.51 (0.47–0.82) 0.56 (0.343–0.98) 0.96
Median percentage COX-2 positive cells 65.3 (60.3–77.4) 22.5 (1.1–60.3) 0.0001 26.6 (12.0–32.4) 9.4 (3.9–18.1) 0.0001
Median COX-2 staining intensity
a 3+ 1+ 0.046 — — —
aNo staining intensity values given for the MDAMB231 cell line as the COX-2 protein was confined to vesicles which could not be quantified by intensity.
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treatment
There was a significant increase in cell apoptosis in the ER-positive
MCF7/HER2-18 cell line following treatment with Celecoxib
(median control TUNEL staining 0.52% (IQR 0.46–0.68), median
treated TUNEL staining 0.77 (IQR 0.46–0.68) (Table 1)). There was
also an increase in apoptosis in the MDAMB231 cell line that did
not reach statistical significance.
Celecoxib inactivates Akt
Akt (PKB) is a member of the serine/threonine kinases, which in
its activated state, is antiapoptotic. Phosphorylation of Akt at the
ser473 site was significantly decreased in the MCF7/HER2-18 cell
line following treatment with Celecoxib, this was shown at both
Western blotting (Figure 1A) and IHC (Figures 2A and B). In the
control samples, pAkt
ser473 was found to be in both the
cytoplasmic and nuclear areas of the cell, and was distributed
throughout the specimen. Celecoxib decreased both the nuclear
and cytoplasmic components of pAkt
ser473 (Figures 2A and B). The
median number of nuclei that stained positive for pAKT
ser473
dropped from 57.3% (IQR 54.1–61.1) in the MCF7/HER2-18
controls to 35.7% (IQR 24.4–47.6%); P¼0.0001. In the ER-
negative MDAMB-231 cell line, no changes in pAkt
ser473 were seen
at either Western blotting (Figure 1B) or IHC (Figure 2C), but as
can be seen from the IHC sections, the distribution of pAkt
ser473 in
the MDAMB231 cell line differed from the MCF7/HER2-18 cell line
in that there was very low levels of nuclear pAkt
ser473 (Figure 2C).
It therefore appears that the subcellular location of pAkt
ser473 is an
important determinant of Celecoxib signalling effect.
COX-2 protein expression
The pattern of COX-2 expression varied between the cell lines. The
MCF7/HER2-18 cell line showed homogeneous cytoplasmic stain-
ing across the majority of cells. Celecoxib treatment decreased
both the median number of positive cells (median control 65.3%
(IQR 60.3–77.4), median treated 22.5 (IQR 1.1–60.3)) and median
staining intensity (Table 1), reflecting a significantly reduced
median immunoscore (Figure 3) of 3 in the treated group,
compared to 6 in the control group (P¼0.0001). However, the
MDAMB231 cell line showed staining that was confined to
cytoplasmic vesicles, and therefore staining intensity could not
be determined and the scoring was based solely on the number of
cells that contained the vesicles. Tumours that had been exposed to
Celecoxib again showed a significantly decreased staining for
COX-2 protein expression (median control 26.6% (IQR 12.0–32.4),
treated 9.4% (IQR 3.9–18.1) (Table 1)). In the ER-positive MCF7/
HER2-18 tumours, the percentage of cells that expressed COX-2 in
the cytoplasm was significantly correlated to growth; correlation
co-efficient 0.4 (P¼0.02).
Lymphangiogenesis
Q-PCR showed a significant decrease in median podoplanin RNA
from the control to the treated tumours. This was seen in both the
MCF7/HER2-18 and the MDAMB231 cell lines. The median
number of RNA copies per ml was 66.61 (IQR 27.87–330.50) in
the MCF7/HER2-18 control and fell to 2.94 copies (IQR 0.27–
18.50) in the treated tumours (P¼0.05) (Table 2). In the
MDAMB231 tumours the median number of RNA copies per ml
was 160.65 in the control tumours (2.14–174.75) and 0.05 (IQR
0.00–2.99) in the treated group (P¼0.015). CD31, a marker of
angiogenesis also showed reduced numbers of RNA following
Celecoxib treatment (Table 2). Our findings were confirmed at the
protein level following immunohistochemical staining for podo-
planin (Figures 2D–G). At IHC the median number of Chalkley
counts in the MCF7/HER2-18 cell line fell from 12 (IQR 9—14) in
the control tumours to 9 (IQR 6–10) in the treated samples
(P¼0.0001), and from 7 (IQR 5–19) in the MDAMB231 tumours,
to 4 (IQR 3–6) in the treated samples (P¼0.0001) (Table 2). At
IHC it could clearly be seen that the majority of lymphatics were in
clusters around the periphery of the tissue; therefore, Western
blots for podoplanin were not performed.
DISCUSSION
COX-2 inhibition decreases tumour growth
High rates of tumour growth and metastasis lead to death from
breast cancer. In the nude mice, median tumour growth was
inhibited by 58.7% in the ER-positive MCF7/HER2-18 tumours and
by 46.3% in the ER-negative MDAMB231 tumours, following
treatment with Celecoxib. Oestrogen receptor-negative tumours
are unresponsive to hormonal manipulation, by way of aromatase
inhibitors and tamoxifen, and conventional treatment options are
therefore limited. Perturbing the COX-2 signalling pathway may
prove to be an important novel therapeutic strategy in both
ER-positive and ER-negative tumours reducing the rate of tumour
growth.
Celecoxib increases apoptosis via inactivation of Akt
The mechanism of action of Celecoxib in inhibiting tumour growth
was by increasing apoptosis. In the MCF7/HER2-18 cell line,
the median number of cells showing apoptosis increased by 40%
from the control to the treated tumours. The fine balance between
apoptosis and proliferation is crucial for regulating growth;
therefore, even the small numerical changes in apoptosis translate
to a large percentage difference, and a significant effect on growth.
There were no discernable changes in cell proliferation. This has
important implications for current and future trials utilising
Celecoxib in breast cancer, as apoptosis, not proliferation should
be used as the primary endpoint. Mechanistically, the increase in
apoptosis was mediated by inactivation of Akt in the MCF7/HER2-
18 cell line. The decrease in pAkt
ser473 that we demonstrated
was predominantly nuclear with a median decease of nuclear
Control Treated
pAKTser473 (60 kDa)
Total AKT (60 kDa) 
Loading control
Loading control
4 3 2 15 6
4 3 2 15 6 7
8 71 0 1 1 1 2 9
8 1 01 11 2 9
MCF7/HER-18 xenografts
MDAMB231 xenografts
pAKTser473 (60 kDa)
Total AKT (60 kDa) 
Control Treated
14 13
A
B
Figure 1 Western blot MCF7/HER2-18 pAkt
ser473, total Akt. (A)
Representative Western blots from MCF7/MCF7/HER2-18 control and
Celecoxib-treated tumours. The top blot shows a decrease in pAKT
ser473
in the treated samples (60kDa). At the bottom, no change was seen in
total AKT (60kDa) as a loading control. The median arbitrary quantity from
the control to treated tumours showed a decrease of 28.2% (IQR  1.5–
89.1%) at densitometry over all of the tumours studied. (B)A
representative Western blot using lysates from the MDAMB231 cell line.
There was no overall pattern seen. Total AKT was used as a loading control
(60kDa), bottom blot.
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Figure 2 The MCF7/HER2-18 control tumours showed expression of pAKT
ser473 in both the cell nucleus and the cell cytoplasm (A). Following Celecoxib
treatment both the nuclear and cytoplasmic components of pAKT
ser473 decreased, this was predominantly seen as a decrease in nuclear pPAKT
ser473 (B),
which decreased from a median of 57.3% (IQR 54.1–61.6) in the control tumours to 35.7% (IQR 24.4–47.6) in the treated tumours, P¼0.0001. The
MDAMB231 cell line expressed predominantly cytoplasmic pAKT
ser473 (C), which did not significantly decrease following Celecoxib treatment. Decreases in
lymphatic vessel density were seen in the MCF7/HER2-18 xenografts (D and E) from a median of 12 Chalkley counts to 9 Chalkley counts (P¼0.0001). The
MDAMB231 xenografts (F and G) also showed a decrease in podoplanin expression from a median of 7 Chalkley counts to 4 Chalkley counts, P¼0.0001)
following COX-2 inhibition. Representative IHC staining for pAKT
ser473 and podoplanin in the harvested xenografts: (A) pAKT
ser473 staining in MCF7/HER2-
18 control xenografts ( 400); (B) pAKT
ser473 staining in MCF7/HER2-18 treated xenografts ( 400); (C) pAKT
ser473 staining in MDAMB231 control
xenografts ( 400); (D) Podoplanin staining in MCF7/HER2-18 control xenografts ( 400); (E) Podoplanin staining in MCF7/HER2-18 treated xenografts
( 400); (F) Podoplanin staining in MDAMB231 control xenografts ( 100); (G) Podoplanin staining in MDAMB231 treated xenografts ( 100).
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sexpression from 57 to 36%. Akt (also known as PKB) is a serine
threonine kinase that acts downstream of PI3 kinase in the
prosurvival pathway. It is thought that activation follows recruit-
ment to the plasma membrane and phosphorylation of both its
serine and threonine residues. It has been demonstrated that
within 30min of activation, Akt detaches from the cytoplasm and
relocates to the nucleus. In the nucleus there is modulation of the
phosphorylation of a variety of transcription factors (Andjelkovic
et al, 1997), including phosphorylation of FKHR1 (Rena et al,
1999) and the forkhead transcription factor AFX (Kops et al, 1999)
promoting their cytoplasmic retention – distancing them from
their nuclear targets. It has previously been shown that the growth
factors PDGF and IGF-1 both cause an increase in the amounts
of intra nuclear Akt (Borgatti et al, 2000). There is still, however,
some debate as to whether activation occurs solely in the
cytoplasm with subsequent translocation to the nucleus, or
whether there is a nuclear component to the event itself (Borgatti
et al, 2000). The subcellular localisation of pAkt is therefore
important for its signalling effect which in the MCF7/HER2-18 cell
line was both cytoplamic and nuclear, but predominantly
cytoplasmic in the MDAMB231’s. This lack of nuclear activated
Akt could explain why there was no decrease in phosphorylation
seen in the MDAMB231 tumours (and a less substantial increase in
apoptosis). Reduced Akt activation following Celecoxib treatment
has also been seen in prostate (Hsu et al, 2000) and hepatocellular
(Leng et al, 2003) cancer cells. The importance of Akt inactivation
in increasing apoptosis was confirmed in PC-3 prostate cancer
cells that were engineered to constitutively overexpress Akt which
showed reduced apoptosis following Celecoxib treatment com-
pared to cells without constitutively active Akt (Hsu et al, 2000).
Celecoxib reduces lymphatic vessel formation
Celecoxib reduced levels of the lymphatic endothelial cell
marker, podoplanin RNA by 87% in the MCF7/HER2-18 and
99.9% in the MDAMB231 tumours. The control samples showed
variable levels of podoplanin RNA (as seen by the interquartile
range values), showing that lymphatic response is specific to the
individual tumour/host. Following Celecoxib treatment this
range was much less variable, with in some cases a complete
lack of expression of podoplanin RNA. The decrease in expression
was also seen at a protein level following Chalkley vessel
counts; where the lymphatic vessels were predominantly clustered
around the tumour periphery. In addition, there was a reduction
in the median number of RNA copies of CD31 (an angiogenic
marker) by 84% in the MCF7/HER2-18 and 91% in the
MDAMB231 tumours. The antiangiogenic properties of the
COX-2 inhibitors have already been demonstrated (Masferrer
et al, 2000). As CD31 and podoplanin RNA were both greatly
reduced in the MDAMB231 tumours, this may account for the
fact that there was decrease in growth of the MDAMB231
tumours following Celecoxib, even though the increase in
apoptosis failed to reach statistical significance. Review of the
IHC sample sections showed large areas of central necrosis in the
MDAMB231-treated tumours, which again would be consistent
with an insufficient blood supply in these Celecoxib-treated
tumours.
In breast cancer the primary mode of metastasis is via the
lymphatics and COX-2 expression correlates with lymph node
metastasis in breast cancer (Ranger et al, 2004). Taken altogether
the cumulating data regarding COX-2 inhibition and lymphangio-
genesis indicate that there is interesting potential of COX-2
inhibitors being used as antimetastatic agents.
Celecoxib decreases COX-2 protein expression
Celecoxib treatment decreased the levels of COX-2 protein
expression in both cell lines. Therefore, Celecoxib is not simply
blocking the effect of COX-2, but is also perturbing COX-2 protein
production; a finding noted in previous studies (Cheng et al, 2002;
Agarwal et al, 2003). In COX-2 expressing HT29 colon cancer cell
lines, COX-2 inhibition with another selective COX-2 inhibitor
SC236 (a structural analogue of Celecoxib) showed that at high
levels of inhibitor (concentrations greater than 75mm), COX-2
enzyme activity was completely inactivated. Decreased levels of
COX-2 protein expression and increases in apoptosis were seen.
Whereas Sulindac sulphide (an inhibitor of COX-1 and COX-2)
did not promote any changes in apoptosis and also showed no
decrease in COX-2 protein expression) (Agarwal et al, 2003). The
antiapoptotic effects of COX-2 were better correlated to decreases
in COX-2 protein expression than inhibition of enzymatic activity
(Agarwal et al, 2003). It has been suggested that the prostaglandin
products of COX-2, mainly PgE2, positively feed back to produce
enhanced COX-2 protein expression (Faour et al, 2001). Therefore
blocking COX-2, and hence prostaglandin production, would
decrease this positive feedback loop. NFkB also regulates the COX-
2 gene. Celecoxib abrogates TNF-induced activation of NFkB with
inhibition of Akt (Shishodia et al, 2004), and therefore another
possible explanation for the decrease in COX-2 protein levels seen
could be that there is inhibition of NFkB-induced promoter
activity of the COX-2 gene, with subsequent decreases in COX-2
protein expression.
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Figure 3 Cyclooxygenase-2 immunoscore in control and Celecoxib-
treated MCF7/HER2-18 tumours. Cyclooxygenase-2 immunoscore was
calculated as the sum of the intensity score 0–4 (0¼none, 1¼mild,
2¼moderate, 3¼strong, 4¼very strong) and the percent positivity score
(0¼nil, 1p10%, 2¼10–50%, 3X50%). No intensity score and therefore
immunoscore could be calculated for the MDAMB231 cell line as the
staining was confined in cytoplasmic vesicles.
Table 2 Q-PCR for lymphangiogenic (podoplanin) and angiogenic (CD31) markers and Podoplanin immunohistochemistry (IHC) Chalkley vessel counts
Cell line
Median RNA copy per ll (IQR)
MCF7/HER2-18
control
MCF7/HER2-18
treated P-value
MDAMB231
control
MDAMB231
treated P-value
Podoplanin 66.61 (27.87–330.50) 2.94 (0.27–18.50) 0.05 160.65 (2.14–174.75) 0.05 (0.00–2.99) 0.02
CD31 47.48 (24.34–56.08) 7.70 (4.50–21.18) 0.08 140.30 (33.84–581.71] 12.87 (3.57–59.69) 0.09
Median Podoplanin IHC Chalkley vessel counts 12 (9–14) 9 (6–10) 0.0001 7 (5–19) 4 (3–6) 0.0001
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In the ER-positive MCF7/HER2-18 treated tumours, the percentage
of residual COX-2 expression significantly correlated with tumour
growth, but in the ER-negative MDAMB231-treated tumours, there
was no correlation between residual COX-2 expression and growth.
This raises the possibility of COX-2 independent effects of
Celecoxib in these ER-negative tumours. Further work needs to
be carried out to explore the possible COX-2 independent effects
of these inhibitors and possible different modes of action in ER-
positive vs ER-negative cases. New generation products, which are
structurally similar to the COX-2 inhibitors, but lack COX-2
inhibiting effects, are currently under development.
Future direction
We have shown that Celecoxib significantly decreases breast
tumour growth in this nude mouse model and clinical studies are
underway to investigate the effect in patient populations.
Cyclooxygenase-2 inhibitors are showing great promise for their
potential therapeutic benefit in a range of cancers; however there
has been recent concern over potential cardiotoxicity. This was
due to an increased risk of cardiovascular events following
treatment with another COX-2 inhibitor Rofecoxib (Vioxx
s –
now withdrawn) that was highlighted following the publication of
the APPROVe trial (Bombardier et al, 2000; Bresalier et al, 2005).
In 2005 the New England Journal of Medicine published a review
of Celecoxib cardiac safety which raised concerns over prolonged
high-dose COX-2 inhibition (Solomon et al, 2005). A review of the
data by Kimmel et al (2005) stated that patients who had been
taking Rofecoxib had a three times greater risk of developing a
myocardial infarction than patients taking Celecoxib, but the
overall safety of Celecoxib is still under debate. As Celecoxib has
now been shown to significantly decrease tumour growth, there is an
urgency to develop new inhibitors that do not have the potential
cardiotoxicity. We must maintain the momentum for further
investigation of this class of drug, and its descendents, in relationship
to their chemotherapeutic potential and mechanisms of action.
In summary, Celecoxib significantly decreased ER-positive and
ER-negative breast tumour growth in our nude mouse xenograft
model. The mechanism of action was via inactivation of AKT
permitting increased cell death in the ER-positive tumours. The
primary mode of breast tumour spread is via the lymphatics.
Increasing evidence suggests that COX-2 has an important role in
lymphangiogenesis and we have shown that COX-2 inhibition
decreases new lymphatic vessel formation with the potential
decrease in metastatic spread of both ER-positive and ER-negative
breast tumours.
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